Skip to main content

Table 2 Univariate and multivariate analysis for variables associated with DFS

From: Association of pre-surgery to pre-radiotherapy lymphocyte counts ratio with disease-free survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy

Clinical factorsUnivariate analysisMultivariable analysis
HR95% CIpHR95% CIp
Age(≥ 59 vs< 59)0.9350.338–3.2551.048   
Sex(F vs M)0.4280.093–1.9800.278   
CEA(≥ 5.0 vs < 5.0)0.9800.315–3.0490.972  
Downstage(n vs y)2.1040.459–9.6530.338   
N status(N+ vs N−)1.9240.610–6.070.264   
Pre-SL(L vs H)3.3630.987–13.6560.052   
Pre-RTL(L vs H)0.4330.095–1.9830.281   
Lnadir(L vs H)1.8040.542–6.0030.336   
Pre-SLR(L vs H)6.2871.374–28.7810.0187.3471.595–33.8500.011
  1. HR, hazard ratio; CI, confidence interval; F, female; M, male; CEA, carcino-embryonic antigen; N, lymph node; N+, lymph node positive; N−, lymph node negative; pre-SL, absolute lymphocyte counts before surgery; pre-RTL, absolute lymphocyte counts before concurrent chemoradiotherapy; Lnadir, the lowest absolute lymphocyte count during concurrent chemoradiotherapy; n, no; y, yes; L, low; H, high